US09073M1045 - Common Stock
BIO-TECHNE CORP
NASDAQ:TECH (12/20/2024, 8:00:01 PM)
After market: 73.17 0 (0%)73.17
+1.78 (+2.49%)
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. The company is headquartered in Minneapolis, Minnesota and currently employs 3,100 full-time employees. The firm's products assist scientific investigations into biological processes and the nature and progress of specific diseases. The Company, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex Bioreactors. Its segments include Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, and tissue biopsy analysis.
BIO-TECHNE CORP
614 Mckinley Pl N E
Minneapolis MINNESOTA 55413
P: 16123798854
CEO: Charles Kummeth
Employees: 3100
Website: https://www.bio-techne.com/
/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the 43rd...
/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leader in automated platforms for biotherapeutic characterization, today announced a co-marketing and...
/PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced that...
/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and...
/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, launched a highly sensitive ESR1 mutation monitoring...
Here you can normally see the latest stock twits on TECH, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: